Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes: The challenges ahead

S.M. Moghimi, Alina Joukainen Andersen, S.H. Hashemi, B. Lettiero, D. Ahmadvand, A.C. Hunter, Thomas Lars Andresen, I. Hamad, J. Szebeni

    Research output: Contribution to journalJournal articleResearchpeer-review

    Abstract

    Since their introduction, poly(ethylene glycol)-phospholipid (PEG-PL) conjugates have found many applications in design and engineering of nanosized delivery systems for controlled delivery of pharmaceuticals especially to non-macrophage targets. However, there are reports of idiosyncratic reactions to certain PEG-PL engineered nanomedicines in both experimental animals and man. These reactions are classified as pseudoallergy and may be associated with cardiopulmonary disturbance and other related symptoms of anaphylaxis. Recent studies suggest that complement activation may be a contributing, but not a rate limiting factor, in eliciting hypersensitivity reactions to such nanomedicines in sensitive individuals. This is rather surprising since PEGylated structures are generally assumed to suppress protein adsorption and blood opsonization events including complement. Here, we examine the molecular basis of complement activation by PEG-PL engineered nanomedicines and carbon nanotubes and discuss the challenges ahead.
    Original languageEnglish
    JournalJournal of Controlled Release
    Volume146
    Issue number2
    Pages (from-to)175-181
    ISSN0168-3659
    DOIs
    Publication statusPublished - 2010
    EventNanomedicine and Drug Delivery - Indianapolis, United States
    Duration: 5 Oct 20096 Oct 2009

    Conference

    ConferenceNanomedicine and Drug Delivery
    CountryUnited States
    CityIndianapolis
    Period05/10/200906/10/2009

    Keywords

    • Micelle
    • Pseudoallergy
    • Poly(ethylene glycol)
    • Complement activation
    • Liposome
    • Carbon nanotube

    Fingerprint Dive into the research topics of 'Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes: The challenges ahead'. Together they form a unique fingerprint.

    Cite this